key: cord-0880415-5k85vc8a
authors: Mahmoudi, Hamidreza; Farid, Ali Salehi; Nili, Ali; Dayani, Dorsa; Tavakolpour, Soheil; Soori, Tahereh; Teimourpour, Amir; Isazade, Ahdie; Abedini, Robabeh; Balighi, Kamran; Daneshpazhooh, Maryam
title: Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: a retrospective cohort study
date: 2020-12-24
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2020.12.043
sha: eb11478c88680f9a72c256c66de20b928cf91f5b
doc_id: 880415
cord_uid: 5k85vc8a

nan

Autoimmune bullous diseases (AIBDs) are a group of blistering conditions whose management 25 is mostly based on immunosuppressive drugs and evidence on their outcomes is limited in the 26 COVID-19 era(1).

This retrospective cohort study on 704 AIBD patients, was conducted in a dermatology referral CoV-2 was detected in 13 (61.9%) patients by RT-PCR and was negative in two (9.6%) patients. The retrospective design, patient admissions in different hospitals, and undetected mild cases 61 were our limitations. In summary, we found a higher risk of COVID-19 and hospitalization with 62 prednisolone>10 mg/day. Also, we showed each passing month from the last dose of RTX 63 decreased these risks. Therefore, patients on long-term prednisolone and recent RTX should be 64 monitored closely. Moreover, physicians should be more vigilant when deciding for RTX 65 administration. Association between prednisolone and rituximab infusion with COVID-19 in patients with autoimmune bullous diseases. * All of 704 patients were included in the "total COVID-19" analysis. For the "diagnosed COVID-19" analysis, highly suspicious cases were excluded from the cohort. Likewise, both highly suspicious and non-hospitalized COVID-19 cases were excluded from the cohort in the "hospitalized COVID-19" analysis. ** Outcomes: Total COVID-19 including diagnosed and highly suspicious cases; diagnosed COVID-19 cases; hospitalized COVID-19 cases. # "RTX interval" was analyzed for patients who received rituximab (RTX) after April 2019 and was defined as the interval from the last dose of RTX to either the date of contracting or May 2020. The blue line shows the relative risk of outcomes with each passing month from the last RTX infusion with a 95% confidence interval. 

Journal of the European Academy of Dermatology and Venereology. 2020. 2. Organization WH. Use of chest imaging in COVID-19: a rapid advice guide

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Response to:'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab'by Avouac et al. Annals of the Rheumatic Diseases